Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Cabaletta captures $74.8m IPO
University of Pennsylvania spinout Cabaletta has gone public after raising $74.8m in an initial public offering on the Nasdaq Global Select Market.
Biontech binds itself to public markets
Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.
Aprea closes $97.8m IPO
The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.
Aprea collects $85m in IPO proceeds
Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
Frequency attracts $84m in IPO
Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.
Beam Therapeutics threads its way toward public markets
Harvard's genomic editing technology spinout has filed to raise up to $100m, adding to some $225m of venture funding in under three years.
Aprea apprises markets ahead of $92m IPO
Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.
Frequency seeks $107m in IPO
Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.

Other News

Satsuma squeezes $82.5m out of IPO
Osage University Partners has celebrated an exit as migraine treatment developer Satsuma Pharmaceuticals listed on the Nasdaq Global Market following an $82.5m offering.
Biontech bids for public markets status
The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.
Aprea opens IPO proceedings
Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.
Satsuma sets course for public markets
Osage University Partners-backed Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.
Codiak revokes $86m IPO filing
Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.
Morphic takes more money in $104m IPO
Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg